Want to see KYTX full AI Analyst Report?
KYTX Stock Chart & Stats
$9.93
-$0.14(-3.63%)
At close: 4:00 PM EST
$9.93
-$0.14(-3.63%)
Day’s Range― - ―
52-Week Range$2.52 - $13.67
Previous CloseN/A
Volume87.17K
Average Volume (3M)842.78K
Market Cap
$540.47M
Enterprise Value$353.65M
Total Cash (Recent Filing)$236.45M
Total Debt (Recent Filing)$33.76M
Price to Earnings (P/E)―
Beta1.82
Next Earnings
Aug 18, 2026EPS Estimate
-0.68Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.28
Shares Outstanding60,795,210
10 Day Avg. Volume719,812
30 Day Avg. Volume842,778
Financial Highlights & Ratios
PEG Ratio-0.28
Price to Book (P/B)1.79
Price to Sales (P/S)0.00
P/FCF Ratio-2.71
Enterprise Value/Market Cap0.65
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-408.37
Enterprise Value/Ebitda-2.30
Forecast
1Y Price Target
$30.00Price Target Upside202.11% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-2.87
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Registrational Phase 2/3 Clinical Success For Miv-celDurable, registrational‑level efficacy and favorable safety across KYSA‑6 and KYSA‑8 materially de‑risks the lead program. A single‑dose, durable clinical profile increases the likelihood of regulatory approval, supports an outpatient commercial model, and underpins sustainable long‑term revenue potential in high‑unmet neuroimmunology niches.
Experienced Commercial Leadership HireBringing a seasoned CCO with decades of launch and neurology/rare disease experience strengthens commercialization capabilities. This hires improves market access, pricing, and launch execution odds, builds durable go‑to‑market capacity, and reduces execution risk as Kyverna readies miv‑cel for potential approval and scale.
Low Leverage And Meaningful Equity CushionA low debt burden and sizable equity base provide financial flexibility relative to typical early‑stage biotechs. Reduced reliance on debt limits refinancing risk, giving management more options to fund pivotal trials, regulatory filings, or initial commercialization activities without immediate pressure from creditors.
Bears Say
Zero Revenue And Widening Net LossesThe absence of product revenue and materially larger losses reflect a company still many milestones from self‑sustaining cash flow. Persisting net losses reduce retained equity, elevate future funding dependence, and make long‑term planning contingent on successful approval or sizeable outside financing that can dilute shareholders.
Large And Accelerating Cash BurnSustained negative operating and free cash flow indicate accelerating cash consumption to support trials and scale‑up. This structural burn rate raises the probability of near‑term financings, which can constrain strategic choices, pressure timelines if capital access tightens, and shift management focus to funding versus execution.
High Concentration On Single Lead Asset (miv‑cel)A business concentrated on one registrational asset creates binary outcome risk: approval, reimbursement or safety setbacks for miv‑cel would disproportionately affect long‑term prospects. Dependence on a single product increases vulnerability to trial delays, regulatory scrutiny, or competitive shifts, reducing portfolio resilience over months.
Kyverna Therapeutics, Inc. News
KYTX FAQ
What was Kyverna Therapeutics, Inc.’s price range in the past 12 months?
Kyverna Therapeutics, Inc. lowest stock price was $2.52 and its highest was $13.67 in the past 12 months.
What is Kyverna Therapeutics, Inc.’s market cap?
Kyverna Therapeutics, Inc.’s market cap is $540.47M.
When is Kyverna Therapeutics, Inc.’s upcoming earnings report date?
Kyverna Therapeutics, Inc.’s upcoming earnings report date is Aug 18, 2026 which is in 46 days.
How were Kyverna Therapeutics, Inc.’s earnings last quarter?
Kyverna Therapeutics, Inc. released its earnings results on May 12, 2026. The company reported -$0.66 earnings per share for the quarter, beating the consensus estimate of -$0.752 by $0.092.
Is Kyverna Therapeutics, Inc. overvalued?
According to Wall Street analysts Kyverna Therapeutics, Inc.’s price is currently Undervalued.
Does Kyverna Therapeutics, Inc. pay dividends?
Kyverna Therapeutics, Inc. does not currently pay dividends.
What is Kyverna Therapeutics, Inc.’s EPS estimate?
Kyverna Therapeutics, Inc.’s EPS estimate is -0.68.
How many shares outstanding does Kyverna Therapeutics, Inc. have?
Kyverna Therapeutics, Inc. has 60,795,210 shares outstanding.
What happened to Kyverna Therapeutics, Inc.’s price movement after its last earnings report?
Kyverna Therapeutics, Inc. reported an EPS of -$0.66 in its last earnings report, beating expectations of -$0.752. Following the earnings report the stock price went up 5.376%.
Which hedge fund is a major shareholder of Kyverna Therapeutics, Inc.?
Currently, no hedge funds are holding shares in KYTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Kyverna Therapeutics, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$30.00 (202.11% Upside)
$30.00 (202.11% Upside)
Blogger Sentiment
Bullish
KYTX Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 2.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 2.1%
Last 30 Days ▼ 2.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
204.69%
12-Months-Change
Fundamentals
Return on Equity
-81.87%
Trailing 12-Months
Asset Growth
-1.39%
Trailing 12-Months
Company Description
Kyverna Therapeutics, Inc.
Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and lupus nephritis, as well as multiple sclerosis and systemic sclerosis. The company is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing; and KYV-201, an allogeneic CD19 CAR T-cell product candidate. It has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.
KYTX Stock 12 Month Forecast
Average Price Target
$30.00
▲(202.11% Upside)
Technical Analysis
Codexis
―
Heron Therapeutics
―
Silence Therapeutics
―
Atea Pharmaceuticals
―
Entrada Therapeutics Inc
―
Ownership Overview
23.23% Insiders
5.87% Mutual Funds
33.70% Other Institutional Investors
29.39% Public Companies and Individual Investors